全球精神分裂症的發病率·企業分析·藥物預測(2010-2015年)

全球精神分裂症的發病率·企業分析·藥物預測(2010-2015年) 是由出版商Renub Research在2011年08月所出版的。 這份英文市場調查報告書包含65 Pages 價格從美金850起跳。

簡介

目前有非常多的精神分裂症治療藥在市場上流通。Zyprexa、Seroquel、Risperdal、Abilify、Geodon等等都是改變了市場動態的暢銷藥，但幾乎所有主要的暢銷藥在2011年到2012年專利都會失效，這也是製造業者最憂心的問題。

本報告提供全球精神分裂症市場相關資料調查分析，主要國家目前患病人口和今後預測，主要治療藥物品牌，主要持續性注射劑的銷售額實際成果與預測，開發平台藥的展望，並彙整主要企業簡介等，為您概述為以下內容。

第1章 摘要整理

第2章 全球精神分裂症市場:過去·現在·未來趨勢

第3章 主要7個國家的發病趨勢

• 美國
  • 精神分裂症的患病人口·未來方案
• 日本
  • 精神分裂症的患病人口·未來方案
• 德國
  • 精神分裂症的患病人口·未來方案
• 法國
  • 精神分裂症的患病人口·未來方案
• 義大利
  • 精神分裂症的患病人口·未來方案
• 英國
  • 精神分裂症的患病人口·未來方案
• 西班牙
  • 精神分裂症的患病人口·未來方案

第4章 全球精神分裂症治療藥物:市場實際成果前10名品牌

• Zyprexa (Olanzapine)
• Seroquel (Quetiapine)
• Geodon
• Risperdal (Risperidone)
• Lonasen
• Serdolect
• Abilify (Aripiprazole)
• Invega (Paliperidone)
• Fanapt (iloperidone)
• Saphris (Asenapine)

第5章 全球精神分裂症持續性注射劑:市場實際成果首位3品牌

• Risperdal Consta (Risperidone)
• Invega Sustenna (Paliperidone Palmitate)
• Relprevv/Zyphdera (Olanzapine LAI)

第6章 開發平台藥:未來趨勢

• Lurasidone
• Staccato (Loxapine Inhalation)
• Cariprazine (RGH-188)
• Pimavanserin

第7章 主要企業

• Eli Lilly and Company
  • 產業概要
  • 優勢·弱點
• Astrazeneca
  • 產業概要
  • 優勢·弱點
• Johnson & Johnson
  • 產業概要
  • 優勢·弱點
• Bristol-Myers Squibb
  • 產業概要
  • 優勢·弱點
• Pfizer
  • 產業概要
  • 優勢·弱點

圖表

目錄

Abstract

Market Overview

Schizophrenia is a mental disorder characterized by disintegration of thought processes and of emotional responsiveness. It most commonly manifests as auditory hallucinations, paranoid or bizarre delusions, or disorganized speech and thinking, or lack of concentration and motivation and it is accompanied by significant social or occupational dysfunction. However with proper medication this disease can be contained to a great extent and Schizophrenia patients can lead a normal healthy life style.

At present lot of drugs for Schizophrenia are available in the market. From the introduction of Clozapine in 1991.Since, 1960, the first atypical antipsychotic to treat schizophrenia, the growth of this class has been rapid. Zyprexa, Seroquel, Risperdal, Abilify, Geodon are the blockbuster drug which has changed the dynamics of the schizophrenia market. But the major worry for the manufactures of these drugs is that by 2011 and 2012 almost all the major blockbuster drugs are going off-patent.

However, depot formulation is the emerging segment which has long term chances of success. The pipeline drug like Lurasidone, Staccato, Cariprazine, Pimavanserin have the comparable efficacy and a similar mechanism of action to that of the existing brands which will enter the market by 2011.

Report Details

“Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast (2010 - 2015)” report published by Renub Research provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally and features latest available data covering:

• Global Schizophrenia Market has been covered from 2004-2019
• Global Schizophrenia patients in 7 countries
• Top 10 Schizophrenia Drug Brands (Zyprexa, Seroquel, Risperdal, Abilify, Geodon, Lonasen, Serdolect, Invega, Fanapt, Saphris) data analysis of Past, Present and Future Market
• Top 3 Schizophrenia Depot Formulations Brands (Risperdal Consta, Invega Sustenna, Relprevv) data analysis of Past, Present and Future Market
• Pipeline Developmental Agents (Lurasidone, Staccato, Cariprazine, Pimavanserin) Future Trends Analyis
• Key Companies Strengths and Weakness analysis in Global Schizophrenia

Research Highlights

• The prevalence of Schizophrenia in United States is expected to reach nearly 4 Million by 2020
• From 2012 onwards Schizophrenia market is expected to show a decline
• Zyprexa is the most successful product in the history of neuroscience
• Abilify hit blockbuster sales in 2006 and it is anticipated that sales will cross US$ 2.5 Billion by 2014.
• Risperdal Consta is the blockbuster injectable form of medicines and predicted that the sale will cross US$ 2 Billion by 2014
• Lurasidone, Staccato, Cariprazine, Pimavanserin are the pipepline drug which will be launched by 2011

Key Companies Analyzed

This section covers the business description, Strengths and Weakness of major players in Global Schizophrenia Market. The key players analyzed in this section are - Eli Lilly and Company, AstraZeneca, Johnson & Johnson, Bristol-Myers Squibb and Pfizer.

Data Sources

Information and data in this report has been collected from various printable and non-printable sources like Trade Journals, White papers, Online paid databases, News websites, Government Agencies, Magazines, Newspapers and Trade associations.

Table of Contents

1. Executive Summary

2. Global Schizophrenia Market Past, Present & Future Trend

3. Prevalence of Schizophrenia in Top 7 Countries

• 3.1. United States of America
  • 3.1.1. Schizophrenia Population & Future Scenario
• 3.2. Japan
  • 3.2.1. Schizophrenia Population & Future Scenario
• 3.3. Germany
  • 3.3.1. Schizophrenia Population & Future Scenario
• 3.4. France
  • 3.4.1. Schizophrenia Population & Future Scenario
• 3.5. Italy
  • 3.5.1. Schizophrenia Population & Future Scenario
• 3.6. United Kingdom
  • 3.6.1. Schizophrenia Population & Future Scenario
• 3.7. Spain
  • 3.7.1. Schizophrenia Population & Future Scenario

4. Global - Top 10 Schizophrenia Drug Brands Market Performance

• 4.1. Zyprexa (Olanzapine)
• 4.2. Seroquel (Quetiapine)
• 4.3. Geodon
• 4.4. Risperdal (Risperidone)
• 4.5. Lonasen
• 4.6. Serdolect
• 4.7. Abilify (Aripiprazole)
• 4.8. Invega (Paliperidone)
• 4.9. Fanapt (iloperidone)
• 4.10. Saphris (Asenapine)

5. Global - Top 3 Schizophrenia Depot Formulations Brand Market Performance

• 5.1. Risperdal Consta (Risperidone)
• 5.2. Invega Sustenna (Paliperidone Palmitate)
• 5.3. Relprevv/Zyphdera (Olanzapine LAI)

6. Pipeline Developmental Agents - Future Trends

• 6.1. Lurasidone
• 6.2. Staccato (Loxapine Inhalation)
• 6.3. Cariprazine (RGH-188)
• 6.4. Pimavanserin

7. Key Companies

• 7.1. Eli Lilly and Company
  • 7.1.1. Business Description
  • 7.1.2. Strength & Weaknesses
• 7.2. Astrazeneca
  • 7.2.1. Business Description
  • 7.2.2. Strength & Weaknesses
• 7.3. Johnson & Johnson
  • 7.3.1. Business Description
  • 7.3.2. Strength & Weaknesses
• 7.4. Bristol-Myers Squibb
  • 7.4.1. Business Description
  • 7.4.2. Strength & Weaknesses
• 7.5. Pfizer
  • 7.5.1. Business Description
  • 7.5.2. Strength & Weaknesses

List of Figure:

• Figure 2 1: Global - Schizophrenia Market (Billion US$), 2004 - 2010
• Figure 2 2: Global - Forecast for Schizophrenia Market (Billion US$), 2011 - 2019
• Figure 3 1: USA - Number of Patients with Schizophrenia Disease (Million), 2005 - 2010
• Figure 3 2: Japan - Number of Patients with Schizophrenia Disease (Million), 2005 - 2010
• Figure 3 3: Germany - Number of Patients with Schizophrenia Disease (Million), 2005 - 2010
• Figure 3 4: France - Number of Patients with Schizophrenia Disease (Million), 2005 - 2010
• Figure 3 5: Italy - Number of Patients with Schizophrenia Disease (Million), 2005 - 2010
• Figure 3 6: UK - Number of Patients with Schizophrenia Disease (Million), 2005 - 2010
• Figure 3 7: Spain - Number of Patients with Schizophrenia Disease (Million), 2005 - 2010
• Figure 4 1: Global - Zyprexa Drug Sales (Million US$), 1999 - 2010
• Figure 4 2: Global - Forecast for Zyprexa Drug Sales (Million US$), 2011 - 2015
• Figure 4 3: Global - Seroquel Drug Sales (Million US$), 1999 - 2010
• Figure 4 4: Global - Forecast for Seroquel Drug Sales (Million US$), 2011 - 2015
• Figure 4 5: Global - Geodon Drug Sales (Million US$), 1999 - 2010
• Figure 4 6: Global - Forecast for Geodon Drug Sales (Million US$), 2011 - 2015
• Figure 4 7: Global - Risperdal Drug Sales (Million US$), 1999 - 2010
• Figure 4 8: Global - Forecast for Risperdal Drug Sales (Million US$), 2011 - 2015
• Figure 4 9: Global - Lonasen Drug Sales (Million US$), 2008 - 2010
• Figure 4 10: Global - Forecast for Lonasen Drug Sales (Million US$), 2011 - 2014
• Figure 4 11: Global - Serdolect Drug Sales (Million US$), 2006 - 2010
• Figure 4 12: Global - Forecast for Serdolect Drug Sales (Million US$), 2011 - 2015
• Figure 4 13: Global - Abilify Drug Sales (Million US$), 2002 - 2010
• Figure 4 14: Global - Forecast for Abilify Drug Sales (Million US$), Q1-2011, 2011 - 2015
• Figure 4 15: Global - Invega Drug Sales (Million US$), 2008 - 2010
• Figure 4 16: Global - Forecast for Invega Drug Sales (Million US$), 2011 - 2015
• Figure 4 17: Global - Forecast for Fanapt Drug Sales (Million US$), 2011 - 2015
• Figure 4 18: Global - Forecast for Saphris Drug Sales (Million US$), 2011 - 2015
• Figure 5 1: Global - Risperdal Consta Drug Sales (Million US$), 2006 - 2010
• Figure 5 2: Global - Forecast for Risperdal Consta Drug Sales (Million US$), 2011 - 2015
• Figure 5 3: Global - Invega Sustenna Drug Sales (Million US$), 2009 - 2010
• Figure 5 4: Global - Forecast for Invega Sustenna Drug Sales (Million US$), 2011 - 2015
• Figure 5 5: Global - Relprevv/Zyphdera Drug Sales (Million US$), 2009 - 2010
• Figure 5 6: Global - Forecast for Relprevv/Zyphdera Drug Sales (Million US$), 2011 - 2015
• Figure 6 1: Global - Forecast for Lurasidone Drug Sales (Million US$), 2011 - 2017
• Figure 6 2: Global - Forecast for Staccato Drug Sales (Million US$), 2010 - 2017
• Figure 6 3: Global - Forecast for Cariprazine Drug Sales (Million US$), 2013 - 2017
• Figure 6 4: Global - Forecast for Pimavanserin Drug Sales (Million US$), 2014 - 2017

List of Tables:

• Table 3 1: USA - Forecast for Number of Patients with Schizophrenia Disease (Million), 2010 - 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
• Table 3 2: Japan - Forecast for Number of Patients with Schizophrenia Disease (Million), 2010 - 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
• Table 3 3: Germany - Forecast for Number of Patients with Schizophrenia Disease (Million), 2011 - 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
• Table 3 4: France - Forecast for Number of Patients with Schizophrenia Disease (Million), 2011 - 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
• Table 3 5: Italy - Forecast for Number of Patients with Schizophrenia Disease (Million), 2011 - 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
• Table 3 6: UK - Forecast for Number of Patients with Schizophrenia Disease (Million), 2010 - 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
• Table 3 7: Spain - Forecast for Number of Patients with Schizophrenia Disease (Million), 2011 - 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
• Table 4 1: Eli Lilly - Challenges to Zyprexa Patents in a number of Countries outside the U.S (2007, 2008 & 2010)
• Table 7 1: Eli Lilly and Company - Key Financial (Million US$), 2008 - 2010
• Table 7 2: Astrazeneca - Key Financial (Million US$), 2008 - 2010
• Table 7 3: Johnson & Johnson - Key Financial (Million US$) 2008 - 2010
• Table 7 4: Bristol-Myers Squibb - Key Financial (Million US$) 2008 - 2010
• Table 7 5: Global - Comparison Chart of Patent Expiry Date of different Blockbuster Drugs
• Table 7 6: Pfizer - Key Financial (Million US$), 2008 - 2010

相關商品

精神病相關市場調查報告書

阿茲海默症：新藥・市場・企業
Alzheimer disease - new drugs, markets and companies
價格 : US $ 3500
出版日期 : 2012年04月

精神醫學相關的各種合作契約：契約條件・合意內容
Psychiatry Partnering Terms and Agreements
價格 : US $ 2695
出版日期 : 2012年03月

R&D趨勢:憂鬱症 - 成熟市場下逐漸減少的治療藥物
R&D Trends: Depression - Clinical attrition driven by mature market conditions
價格 : US $ 3800
出版日期 : 2012年01月

Renub Research發行的製藥相關市場調查報告書

泰國的醫療旅遊:遊客數及市場規模的預測(∼2015年)

Thailand Medical Tourist Arrivals, Medical Tourism Market & Forecast to 2015

價格 : US $ 800

出版日期 : 2012年04月

C型肝炎(HCV)市場預測及藥物開發平台分析:∼2016年

Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016

價格 : US $ 975

出版日期 : 2012年01月

全球流感疫苗市場:市場機會·課題·市場預測

Influenza Vaccine Market Opportunities and Challenges: Worldwide Forecast

價格 : US $ 1100

出版日期 : 2012年01月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!